SCHEMBL25239803

SCHEMBL25239803

CC(C)(C)OC(=O)NCc1ncnn1-c1ccc(Cl)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.42
STK17A Q9UEE5 1/20 0.42
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
GFER P55789 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
MAPKAPK2 P49137 2/20 0.36
PCSK9 Q8NBP7 1/20 0.36
PDPK1 O15530 1/20 0.36
TRPA1 O75762 1/20 0.35
NAMPT P43490 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25218981 0.87 SMO (0.43) STK17BSTK17APOLBMAPK1ATM
SCHEMBL25214552 0.87 CA1 (0.39) STK17BSTK17APOLBMAPK1ATM
SCHEMBL25218913 0.84 IDO1 (0.40) POLBMAPK1KDM4EL3MBTL1PCSK9
SCHEMBL29417983 0.84 IDO1 (0.40) POLBMAPK1KDM4EL3MBTL1PCSK9
SCHEMBL25270165 0.84 GFER (0.41) KDM4ELMNAGFERL3MBTL1HSD17B10
SCHEMBL25254440 0.83 POLB (0.41) STK17BSTK17APOLBMAPK1ATM
SCHEMBL25213983 0.82 GFER (0.39) KDM4ELMNAGFERL3MBTL1HSD17B10
SCHEMBL25409784 0.80 KDM4A (0.43) KDM4ELMNAGFERL3MBTL1HSD17B10
SCHEMBL23976369 0.78 GFER (0.46) POLBMAPK1ATMKDM4ELMNA
SCHEMBL25242692 0.78 LMNA (0.39) STK17BSTK17APOLBMAPK1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-09-07 US disclosed
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-09-07 US disclosed
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-09-07 US disclosed
EP-4188542-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS Global Blood Therapeutics, Inc. (US) 2023-06-07 EP disclosed
WO-2022031735-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278984-A1 UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS PKM, PDK1, PDK2 STK17B 188/4885STK17A 157/4885POLB 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.